[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100356494":3},{"organization":4,"armGroups":7,"interventions":37,"overallOfficials":12,"centralContacts":12,"locations":12,"responsibleParty":51,"collaborators":12,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":12,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":12,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":85,"whyStopped":12,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":12},{"fullName":5,"class":6},"Poznan University of Medical Sciences","OTHER",[8,13,19,24,29,33],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group","NO_INTERVENTION","Control group consisted of 40 postmenopausal women with normal blood pressure.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Hypertensive women group receiving hydrochlorothiazide","EXPERIMENTAL","Patients received hydrochlorothiazide 25 mg\u002Fday p.o. for 1 year.",[18],"Drug: Hydrochlorothiazide",{"label":20,"type":15,"description":21,"interventionNames":22},"Hypertensive women group receiving perindopril.","Patients received perindopril 4 mg\u002Fday p.o for 1 year.",[23],"Drug: Perindopril",{"label":25,"type":15,"description":26,"interventionNames":27},"Hypertensive women group receiving hydrochlorothiazide and EPT","Patients received hydrochlorothiazide 25 mg\u002Fday p.o. and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg\u002F24 hours) and norethisterone (0.25 mg\u002F24 hours) for 1 year",[18,28],"Drug: Estracomb TTS",{"label":30,"type":15,"description":31,"interventionNames":32},"Hypertensive women group receiving perindopril and EPT.","Patients received perindopril 4 mg\u002Fday p.o and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg\u002F24 hours) and norethisterone (0.25 mg\u002F24 hours) for 1 year",[23,28],{"label":34,"type":15,"description":35,"interventionNames":36},"Hipotensive women group receiving EPT.","Patients received estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg\u002F24 hours) and norethisterone (0.25 mg\u002F24 hours) for 1 year.",[28],[38,43,47],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":12},"DRUG","Perindopril","4 mg\u002Fday p.o. for 12 months",[30,20],{"type":39,"name":44,"description":45,"armGroupLabels":46,"otherNames":12},"Hydrochlorothiazide","hydrochlorothiazide 25 mg\u002Fday p.o. for 12 months",[14,25],{"type":39,"name":48,"description":49,"armGroupLabels":50,"otherNames":12},"Estracomb TTS","Transdermal patches releasing 17β-estradiol (0.05 mg\u002F24 hours) and norethisterone (0.25 mg\u002F24 hours) for 12 months",[34,25,30],{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"SPONSOR_INVESTIGATOR","Anna Posadzy-Małaczyńska","Habilitated doctor of Medical Sciences in Medicine","100356494","phase-4-reversal-of-an-unfavorable-effect-of-hydrochlorothiazide-compared-to-angiotensin-converting-enzyme-inhibitor-on-serum-uric-acid-and-oxypurines-levels-by-estrogen-progestin-therapy-in-hypertensive-postmenopausal-women-100356494",false,"NCT03921736","Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.","Inclusion Criteria:\n\n* Treatment-naive postmenopausal women\n* Diagnosed hypertension (grade 1 or 2 according to ESH\u002FESC 2013 guidelines)\n\nExclusion Criteria:\n\n* breast cancer in a first-degree relative\n* hyperplasia diagnosed by endometrial biopsy,\n* history of thromboembolic diseases,\n* current or history of use of estrogen-progestin therapy or contraceptives\n* diabetes,\n* kidney failure,\n* thyroid disease,\n* heart and other chronic diseases (secondary hypertension, atrial fibrillation)",true,"FEMALE","49 Years","53 Years",{"count":66,"type":67},180,"ACTUAL","INTERVENTIONAL",[70],"PHASE4","The aim was to assess the effect of estrogen-progestin therapy (EPT) on serum levels of uric acid (SUA) and its precursors: xanthine (X) and hypoxanthine (HX) and on uric acid (UA) renal excretion in hypertensive postmenopausal women treated with an angiotensin-converting enzyme inhibitor (ACEI) or thiazide diuretic (HCTZ).",[73,74,75],"Hypertension","Hyperuricemia","Menopause",[77,78,79,80,81,82,83,84],"estrogen-progestin therapy","hypertension","uric acid","xanthine","hypoxanthine","menopause","thiazide diuretic","angiotensin-converting enzyme inhibitor","COMPLETED","2019-04-18",{"date":88,"type":67},"2019-04-22",{"date":90,"type":67},"2000-01-10",{"date":92,"type":67},"2005-11-17",{"name":53,"class":6}]